Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREOPANC trial of preoperative chemoradiotherapy versus upfront surgery for resectable or borderline resectable pancreatic cancer
NL-OMON22251Phase 3Not yet recruiting
- Sponsor
- Academic Medical Center Department of radiation oncology Meibergdreef 9 1105 AZ Amsterdam The Netherlands Phone: +31 20 5665591 E-mail: [email protected]
- Start
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemcitabine in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Academic Medical Center Department of radiation oncology Meibergdreef 9 1105 AZ Amsterdam The Netherlands Phone: +31 20 5665591 E-mail: [email protected]. Primary endpoint: Overall survival. Planned start Jan 2013; status: not yet recruiting.
02
Drugs
gemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON22251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22251.